

17 May 2017

Executive Chair Remuneration Update

In recognition of the activity that the Board has agreed will be under the direction of the Executive Chair, it has been recommended by the Remuneration Committee that the 4 million unlisted options granted to the Chairman at the 2016 AGM will be cancelled and replaced with 10 million unlisted options exercisable at A\$0.075 on or before 31 December 2018 and 10 million unlisted options exercisable at A\$0.10 on or before 30 June 2021. The grant of options will be subject to Shareholder Approval at the 2017 AGM.

Respiri is on track to develop one or more partnerships that will accelerate commercialisation of its technology.

Dr. Timothy Oldham
Remuneration Committee Chairman
Ph: 1800 476 632

About Respiri Limited

Respiri Limited (ASX:RSH) is a medical technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting-edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices. Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respiri's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respiri has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respiri products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun.